Tag:
Zogenix
Latest Headlines
Latest Headlines
After Astellas fallout, Zogenix strikes deal with Battelle to market DosePro
The company has wasted little time finding another marketing partner, inking a one-year deal with Battelle to promote the needle-free platform.
Zogenix plots marketing app as pain drug clears PhIII
Zogenix announced that its chronic pain drug had aced a late-stage study, putting it on track for a marketing application in early 2012. But the news did little for its share price ( $ZGNX ), which has
Durect, Zogenix in deal for drug that could rival major J&J treatment
Durect has bounced back some from a regulatory setback last month with a brand new pact with developer Zogenix. The two companies struck a deal to develop a long-acting version of the antipsychotic
Uphill climb gets even steeper for biotech IPOs
Wall Street may have had its arms open wide for GM's new market debut, but drug developers are finding the same chilly disdain for red ink that has greeted almost every offering this year. Zogenix
Zogenix aims for $78M with IPO
San Diego's Zogenix says it plans to sell $6 million in stock for $12 to $14 a share, which would allow the company to raise $78 million if it prices at the midpoint of that range. Zogenix had
Migraine sufferers get 'satisfaction' from Sumavel DosePro
As migraine sufferers can attest, there is potential big business for any company that can deliver long-lasting, immediate relief. San Diego-based Zogenix is literally staking its future on it. As
Zogenix files for $90M IPO
After gathering a $200 million mix of venture funding and debt finance, San Diego-based Zogenix has filed an IPO intended to raise $90 million. The biotech company does have a product on the market:
San Diego biotechs see increased revenue
San Diego-based biotech firms have weathered the recent economic downturn by cutting both employees and underperforming drug development programs. The city's public biotechs saw their net loss
Zogenix pushes its Series B to $71M
San Diego-based Zogenix has piled an additional $20 million on its Series B, bringing its total for the round to a whopping $71 million as it builds up a cache of cash for a planned launch of its
Zogenix rounds up $51M for product roll-out
Zogenix has ginned a hefty $51 million Series B preferred stock financing to fund the roll-out of the company's first product. Clarus Ventures and Domain Associates co-led the round, and were joined
